-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US17331Y1091 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Market Cap | 132M |
|---|---|
| Target Price | None |
| Beta | 3.02 |
| PE Ratio | None |
| Dividend Yield | None |
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CTOR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025